On Tuesday, Zealand Pharma secured a USD 50m option for potential acquisitions of products or companies in a financing agreement with private investment firm Oberland Capital.
However, with clinical trials underway and its goal of having five products on the market in 2025, Zealand Pharma is already well-armed in this business area, CEO at Zealand Pharma Emmanuel Dulac tells MedWatch. Funding from the option, which much be exercised before June 30, 2023, would likely be spent elsewhere.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.